₹196.91
▼ -3.67 -1.83%
As of 09 Sept 2026 · delayed
NSE Listed
Sun Pharma Advanced Research Company Ltd. (SPARC)
Volume: 5,19,851Avg Vol 1W: 8,56,055.2Avg Vol 1M: 8,94,449.7552W Range:₹108₹289
Key Ratios
Checked 8h agoMarket Cap₹6,509 Cr
Current Price₹196.91
Previous Close₹200.58
High / Low (52w)₹289 / ₹108
Volume5,19,851
Avg Vol (1W)8,56,055.2
Avg Vol (1M)8,94,449.75
Stock P/E-14.03
Book Value₹-6.68
Dividend Yield—
ROE0%
ROA—
Revenue (TTM)₹74 Cr
Revenue Growth—
Profit Margin—
Total Debt₹100 Cr
Shares Outstanding—
Face Value₹1
EPS (TTM)₹-10.55
P/B-22.16
Debt / Equity0
50 DMA₹217.82
200 DMA₹171.74
Day change-1.83%
Price Chart
₹196.91▲ 36.80% · 1Y
2025-09-102026-09-09
20-day avg volume: 8.9L shares
Pros
- Company is almost debt-free.
Cons
- Revenue fell 66% YoY.
- Company is loss-making at the latest annual result.
- Negative book value per share.
Quarterly Results
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹13 Cr | ₹15 Cr | ₹27 Cr | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹1,853 Cr | ₹40 Cr |
| EBITDA | ₹-106 Cr | ₹-77 Cr | ₹-56 Cr | ₹-46 Cr | ₹-68 Cr | ₹-59 Cr | ₹1,773 Cr | ₹-13 Cr |
| Net Profit | ₹-107 Cr | ₹-80 Cr | ₹-60 Cr | ₹-52 Cr | ₹-76 Cr | ₹-80 Cr | ₹1,761 Cr | ₹-21 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹27 Cr | ₹74 Cr | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹1,853 Cr | ₹1,890 Cr | ₹40 Cr |
| EBITDA | ₹-56 Cr | ₹-334 Cr | ₹-46 Cr | ₹-68 Cr | ₹-59 Cr | ₹1,772 Cr | ₹1,600 Cr | ₹-13 Cr |
| Net Profit | ₹-61 Cr | ₹-343 Cr | ₹-52 Cr | ₹-76 Cr | ₹-81 Cr | ₹1,761 Cr | ₹1,553 Cr | ₹-21 Cr |
| EPS | — | -10.55 | — | — | — | — | 47.86 | — |
Balance Sheet
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹273 Cr | ₹230 Cr | ₹280 Cr | ₹830 Cr | ₹515 Cr | ₹336 Cr | ₹2,171 Cr |
| Total Liabilities | ₹291 Cr | ₹398 Cr | ₹249 Cr | ₹317 Cr | ₹389 Cr | ₹552 Cr | ₹832 Cr |
| Equity | ₹-19 Cr | ₹-168 Cr | ₹31 Cr | ₹513 Cr | ₹126 Cr | ₹-217 Cr | ₹1,339 Cr |
| Total Debt | ₹6 Cr | ₹113 Cr | ₹0 Cr | — | — | — | — |
Cash Flow
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | ₹-150 Cr | ₹-213 Cr | ₹-74 Cr | ₹-425 Cr | ₹-369 Cr | ₹-270 Cr |
| Investing | ₹2 Cr | ₹-29 Cr | ₹-548 Cr | ₹392 Cr | ₹158 Cr | ₹-23 Cr |
| Financing | ₹159 Cr | ₹229 Cr | ₹617 Cr | ₹42 Cr | ₹199 Cr | ₹261 Cr |
| Free Cash Flow | ₹-150 Cr | ₹-213 Cr | ₹-74 Cr | ₹-425 Cr | ₹-369 Cr | ₹-270 Cr |
Shareholding
Promoter 65.67% Institutions 4% Public 30.33%
Efficiency & Working Capital
ROCE80.9%
Interest Coverage46.5
Dividend Payout—
Debtor Days2 d
Inventory Days0 d
Payable Days19 d
Cash Conversion Cycle-17 d
Working Capital Days2 d
Shareholding Details
As of 2026-06-30
Promoter65.7%
FII3.9%
DII0.1%
Institutions4%
Public30.3%
Promoter Pledge0%
No. of Shareholders1,41,957
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | May 2026 | May 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 65.7% | 65.7% | 65.7% | 65.7% | 65.7% | 65.7% | 65.7% | 65.7% | 65.7% | 65.7% | 65.7% | 65.7% |
| FIIs | 3.2% | 2.6% | 2.1% | 2.2% | 1.4% | 1.5% | 1.8% | 2% | 2% | 2.5% | 2.5% | 3.9% |
| DIIs | 0.8% | 0.2% | 0.2% | 0.6% | 1.1% | 1% | 1% | 0.8% | 0.9% | 0.1% | 0.1% | 0.1% |
| Public | 30.3% | 31.5% | 32% | 31.5% | 31.8% | 31.9% | 31.5% | 31.5% | 31.4% | 31.8% | 31.8% | 30.3% |
| Promoter Pledge | 2.8% | 2.8% | 2.8% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 1,02,743 | 1,25,184 | 1,28,205 | 1,31,034 | 1,42,864 | 1,40,724 | 1,36,997 | 1,44,810 | 1,40,625 | 1,37,538 | 1,37,538 | 1,41,957 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Shanghvi Finance Private Limited | Shareholding of Promoter and Promoter Group | 42.3% | 13.72 Cr |
| Dilip.s.shanghvi | Shareholding of Promoter and Promoter Group | 19.1% | 6.18 Cr |
| Sun Pharmaceutical Industries Key Employees Benefit Trust | Public Shareholding | 3.2% | 1.03 Cr |
| Lakshdeep Investments & Finance (p) Ltd. | Public Shareholding | 1.9% | 60,33,835 |
| Aditya Medisales Limited | Shareholding of Promoter and Promoter Group | 1.5% | 48,88,126 |
| Raksha Sudhir Valia | Shareholding of Promoter and Promoter Group | 1.3% | 41,45,231 |
| Paresh Mohanlal Parekh | Public Shareholding | 1.1% | 36,51,837 |
| Vijay Mohanlal Parekh | Public Shareholding | 1.1% | 36,65,304 |
| Enam Securities Private Limited | Public Shareholding | 1% | 33,70,786 |
| Sudhir Vrundavandas Valia | Shareholding of Promoter and Promoter Group | 0.6% | 18,33,951 |
| Unimed Investments Limited | Shareholding of Promoter and Promoter Group | 0.4% | 12,67,963 |
| Vibha Dilip Shanghvi | Shareholding of Promoter and Promoter Group | 0.3% | 10,63,236 |
| Aalok Dilip Shanghvi | Shareholding of Promoter and Promoter Group | 0.1% | 3,50,162 |
| Vidhi Dilip Shanghvi | Shareholding of Promoter and Promoter Group | 0.1% | 3,44,081 |
| Shanghvi Family & Friends Benefit Trust | Shareholding of Promoter and Promoter Group | 0.1% | 1,54,922 |
| Kumud Shantilal Shanghvi | Shareholding of Promoter and Promoter Group | 0% | 38,795 |
| Krishna Vrundavandas Valia | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Flamboyawer Finance Private Limited | Shareholding of Promoter and Promoter Group | 0% | 2,543 |
| Shanghvi Universal Private Limited | Shareholding of Promoter and Promoter Group | 0% | 1,887 |
| Sun Petro Private Limited | Shareholding of Promoter and Promoter Group | 0% | 1,751 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Dilip S Shanghvi | Chairman & Non Executive Dir. | 2026 |
| Vidhi Shanghvi | Non-Exec & Non-Independent Dir | 2026 |
| T Rajamannar | Non Executive Director | 2026 |
| Robert Spiegel | Independent Non Exe. Director | 2026 |
| Venkateswarlu Jasti | Independent Non Exe. Director | 2026 |
| Rekha Warriar | Independent Non Exe. Director | 2026 |
| Kajal Damania | Company Sec. & Compli. Officer | 2026 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceuticals Research & Developm | ₹0 Cr | — |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| Within India | ₹38 Cr | 97.2% |
| Outside India | ₹1 Cr | 2.8% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹1 | 43 | 32 | 32 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-08-10 | Board Meetings | — |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2026 | 3 | 0 | 0 | 6 | -114 | -105 |
| 2026 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 3 | 0 | 0 | 6 | -153 | -144 |
Insider / Designated-Person Trades
10 recent disclosure(s)
SUDHIR VALIAPledge · 18,00,000
RAKSHA VALIAPledge · 22,00,000
Dilip S. ShanghviAcquisition · 2,52,80,899
RAKSHA VALIAPledge · 19,00,000
Raksha ValiaPledge · 30,80,000
Raksha ValiaPledge · 10,00,000
Substantial Acquisitions (SAST)
1 disclosure(s)
Pref. Allotment19/05/2026 · 3,85,10,000
Company Information
🌐 www.sparc.life ↗
📍 Sun Pharma Advanced Res Centre, Akota Road Akota, Vadodara, Gujarat, 390020
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Sotac Pharmaceuticals Ltd.Savita Oil Technologies Ltd.South Indian BankSouth West Pinnacle Exploration Ltd.SP Apparels LimitedSpandana Sphoorty Financial Ltd.Spacenet Enterprises India Ltd.Shivalic Power Control LimitedSrinibas Pradhan Constructions Ltd.Speb Adhesives LimitedSpeciality Restaurants Ltd.Spectrum Electrical Industries Ltd.All “S” stocks →
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search